Caffeamide 36-13 Regulates the Antidiabetic and Hypolipidemic Signs of High-Fat-Fed Mice on Glucose Transporter 4, AMPK Phosphorylation, and Regulated Hepatic Glucose Production

Figure 2

(a) Effects of caffeamide 36-13 (TS) on oral glucose tolerance in normal mice. Animals in all groups received oral glucose 30 minutes after TS administration. Blood samples were collected and centrifuged at 3000 rpm for 10 minutes. Each point is the mean ± S.E. of 5 separate mice. ^∗∗𝑃<0.01, ^∗∗∗𝑃<0.001 significantly different compared with the control group in the same time by ANOVA. (b) Effects of caffeamide 36-13 (TS) on body weight. Mice were fed with 45% high-fat diet (HF) or low-fat diet (CON) for 12 weeks. After 8 weeks, the HF mice were treated with vehicle or TS or rosiglitazone (Rosi) accompanied with HF diet for 4 weeks. All values are means ± S.E. (𝑛=9). ^###𝑃<0.001 compared with the control (CON) group by ANOVA. TS: T1:10, T2: 20 mg/kg bodyweight; Rosi: rosiglitazone (0.01 g/kg body weight). WAT, white adipose tissue; epididymal WAT + retroperitoneal WAT, visceral fat.

(a)

(b)